Charles Schwab
HOWL icon

Charles Schwab’s Werewolf Therapeutics HOWL Stock Holding History

Charles Schwab’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-95,712
Closed -$93.1K – 3527
2025
Q1 		$93.1K Buy
95,712
+23,852
+33% +$31.2K ﹤0.01% 3355
2024
Q4 		$106K Sell
71,860
-6,982
-9% -$14.2K ﹤0.01% 3393
2024
Q3 		$167K Hold
78,842
– – ﹤0.01% 3353
2024
Q2 		$192K Buy
+78,842
New +$379K ﹤0.01% 3443
2022
Q2 		– Sell
-60,646
Closed -$267K – 3587
2022
Q1 		$267K Buy
60,646
+52
+0.1% +$364 ﹤0.01% 3247
2021
Q4 		$722K Buy
60,594
+41,172
+212% +$621K ﹤0.01% 3036
2021
Q3 		$334K Buy
19,422
+3,384
+21% +$57.7K ﹤0.01% 3240
2021
Q2 		$280K Buy
+16,038
New +$220K ﹤0.01% 3250

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Charles Schwab's HOWL Position: Q2 2025 in Review

Charles Schwab sold out of Werewolf Therapeutics (HOWL) in Q2 2025, closing a stake of 95,712 shares — an estimated $93.1K sold.

Charles Schwab first reported a position in HOWL in Q2 2021 and held it in 8 quarters. The position peaked at $722K in Q4 2021. 65 funds tracked by Wall St. Rank hold HOWL as of Q2 2025.

  • Charles Schwab reported no remaining Werewolf Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Charles Schwab sold 95,712 Werewolf Therapeutics shares in Q2 2025, an estimated $93.1K.
  • Charles Schwab first reported a position in Werewolf Therapeutics in Q2 2021 and held it in 8 quarters.
  • Charles Schwab's Werewolf Therapeutics position peaked at $722K in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.